BUY Neogen Chemicals Limited — ICICI Securities
byICICI SecuritiesHorizon: NA (inferred 1 year)28 Sept 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·28 Sept · today
CRISIL has revised the outlook on Neogen Chemicals Ltd's long-term bank facilities and debt instruments from 'Negative' to 'Stable', reaffirming the rating. This revision reflects improved financial r
BSE · Company Update·26 Sept · 2d ago
Neogen Chemicals Share Price Rises Over 1% After Rs 600 Crore QIP Receives Strong Demand
NewsNdtv-Profit·22 Sept · 6d ago
Neogen Chemicals: 1st ever QIP raises ₹600 cr; oversubscribed by 6.5x at ₹2,255 share price, stock up 102% in 2026
NewsLivemint·22 Sept · 6d ago
Neogen Chemicals Ltd has successfully raised approximately INR 600 crore through its first Qualified Institutional Placement (QIP) issue, which was oversubscribed by 6.5 times.
BSE · Company Update·21 Sept · 1w ago
Abu Dhabi Investment Authority among others issued shares in Neogen Chemicals' ₹600 crore QIP
NewsCnbc-Tv18·17 Sept · 2w ago
₹600 cr Neogen QIP: Floor price, key dates, discount option, approvals and other details
NewsLivemint·11 Sept · 2w ago
Neogen Chemicals sets QIP floor price at ₹2,190, offers up to 5% discount
NewsCnbc-Tv18·10 Sept · 3w ago
Neogen Chemicals Ltd's Fund-Raising Committee approved the opening date and floor price for its Qualified Institutions Placement (QIP). The floor price is set at ₹2,189.73 per equity share.
BSE · Company Update·10 Sept · 3w ago
Neogen Chemicals arm to transfer LiPF6 business to step-down subsidiary for ₹245 crore
NewsCnbc-Tv18·1 Sept · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

